Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$2.25 -1.7%	$2.67	$1.78 ▼ $10.14	$47.00M	0.71	270,416 shs	173,955 shs
ATRA Atara Biotherapeutics	$7.94 -1.0%	$7.49	$5.01 ▼ $18.71	$47.32M	0.19	123,967 shs	86,856 shs
INMB INmune Bio	$6.38 -11.9%	$7.52	$4.32 ▼ $10.50	$146.61M	1.55	304,937 shs	1.49 million shs
SOPH SOPHiA GENETICS	$3.04	$2.97	$2.58 ▼ $4.92	$202.74M	1	59,735 shs	1.91 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	0.00%	-8.54%	+1.81%	-58.33%	-66.57%
ATRA Atara Biotherapeutics	0.00%	-9.98%	+11.20%	+14.41%	-3.52%
INMB INmune Bio	0.00%	-17.14%	-12.60%	-23.13%	-13.90%
SOPH SOPHiA GENETICS	0.00%	+5.92%	+6.67%	-2.56%	-35.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADVM Adverum Biotechnologies	3.8209 of 5 stars	3.4	1.0	4.8	1.3	2.5	0.6
ATRA Atara Biotherapeutics	3.9718 of 5 stars	3.3	3.0	4.7	0.6	2.5	0.6
INMB INmune Bio	2.1377 of 5 stars	3.6	0.0	0.0	3.3	1.7	0.6
SOPH SOPHiA GENETICS	1.5318 of 5 stars	3.4	3.0	0.0	0.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADVM Adverum Biotechnologies	2.80	Moderate Buy	$26.40	1,073.33% Upside
ATRA Atara Biotherapeutics	2.57	Moderate Buy	$17.75	123.55% Upside
INMB INmune Bio	3.17	Buy	$22.80	257.37% Upside
SOPH SOPHiA GENETICS	2.75	Moderate Buy	$6.80	123.68% Upside

Current Analyst Ratings Breakdown

Latest ATRA, SOPH, ADVM, and INMB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$5.00 ➝ $4.00
5/15/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
5/15/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
4/17/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $33.00
4/16/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$10.00 ➝ $5.00
4/16/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADVM Adverum Biotechnologies	$1M	47.00	N/A	N/A	$3.40 per share	0.66
ATRA Atara Biotherapeutics	$128.94M	0.37	N/A	N/A	($16.89) per share	-0.47
INMB INmune Bio	$10K	14,661.24	N/A	N/A	$1.45 per share	4.40
SOPH SOPHiA GENETICS	$65.17M	3.11	N/A	N/A	$1.48 per share	2.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADVM Adverum Biotechnologies	-$130.93M	-$6.40	N/A	N/A	N/A	N/A	-130.53%	-66.31%	8/11/2025 (Estimated)
ATRA Atara Biotherapeutics	-$85.40M	-$3.72	N/A	N/A	N/A	-7.83%	N/A	-14.51%	8/11/2025 (Estimated)
INMB INmune Bio	-$42.08M	-$1.93	N/A	N/A	N/A	N/A	-119.35%	-89.37%	7/30/2025 (Estimated)
SOPH SOPHiA GENETICS	-$62.49M	-$1.00	N/A	N/A	N/A	-98.51%	-63.47%	-40.06%	8/5/2025 (Estimated)

Latest ATRA, SOPH, ADVM, and INMB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ATRA Atara Biotherapeutics	-$3.07	$3.50	+$6.57	$3.50	$4.30 million	$98.10 million
5/8/2025	Q1 2025	INMB INmune Bio	-$0.43	-$0.43	N/A	-$0.43	N/A	$0.05 million
5/6/2025	Q1 2025	SOPH SOPHiA GENETICS	-$0.21	-$0.26	-$0.05	-$0.26	$16.76 million	$17.78 million
4/15/2025	Q4 2024	ADVM Adverum Biotechnologies	-$1.34	-$1.96	-$0.62	-$1.96	N/A	N/A
3/27/2025	Q4 2024	INMB INmune Bio	-$0.54	-$0.40	+$0.14	-$0.40	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
SOPH SOPHiA GENETICS	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADVM Adverum Biotechnologies	N/A	3.57	3.57
ATRA Atara Biotherapeutics	N/A	0.57	0.57
INMB INmune Bio	N/A	2.64	2.64
SOPH SOPHiA GENETICS	0.16	3.11	2.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADVM Adverum Biotechnologies	48.17%
ATRA Atara Biotherapeutics	70.90%
INMB INmune Bio	12.72%
SOPH SOPHiA GENETICS	31.59%

Insider Ownership

Company	Insider Ownership
ADVM Adverum Biotechnologies	6.00%
ATRA Atara Biotherapeutics	4.00%
INMB INmune Bio	35.70%
SOPH SOPHiA GENETICS	4.88%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADVM Adverum Biotechnologies	190	20.89 million	19.64 million	Optionable
ATRA Atara Biotherapeutics	330	5.96 million	5.72 million	Optionable
INMB INmune Bio	10	22.98 million	14.78 million	Optionable
SOPH SOPHiA GENETICS	520	66.69 million	63.43 million	Not Optionable

ATRA, SOPH, ADVM, and INMB Headlines

Recent News About These Companies

Enough hype about AI in health—let’s talk about results

June 12, 2025 | fastcompany.com

M42, AstraZeneca, and SOPHiA GENETICS launch UAE broad liquid biopsy initiative to transform cancer diagnosis and care

June 3, 2025 | zawya.com

M42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, care

June 3, 2025 | msn.com

M42, partners launch liquid biopsy testing in UAE

June 3, 2025 | tradearabia.com

The Multimodal Imperative: How AI-Driven Technology is Driving Impactful Changes

June 2, 2025 | fiercepharma.com

SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Update

June 1, 2025 | marketbeat.com

'An unusual precedent': Baby Sophia's genetic parents demand new Supreme Court hearing

May 28, 2025 | israelnationalnews.com

High Court grants custody of IVF baby to adoptive, not biological parents

May 12, 2025 | msn.com

SOPHiA GENETICS First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

May 12, 2025 | uk.finance.yahoo.com

Supreme Court: IVF mixup baby to remain with birth parents

May 12, 2025 | israelnationalnews.com

Supreme Court upholds decision to keep IVF child with birth mother following embryo mix-up

May 12, 2025 | msn.com

Supreme Court rules birth parents of child born in IVF mix-up are legal parents

May 12, 2025 | msn.com

The Sophia Case: When Parenthood Isn’t Just About Genetics

May 10, 2025 | blogs.timesofisrael.com

SOPHiA GENETICS SA (SOPH) Q1 2025 Earnings Call Transcript

May 10, 2025 | seekingalpha.com

Sophia Genetics SA (SOPH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Improved ...

May 7, 2025 | finance.yahoo.com

SOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue Estimates

May 6, 2025 | zacks.com

SOPHiA GENETICS Reports First Quarter 2025 Results

May 6, 2025 | prnewswire.com

SOPHiA GENETICS expands AstraZeneca liquid biopsy test

April 30, 2025 | investing.com

SOPHiA GENETICS Expands AstraZeneca Partnership to Advance Liquid Biopsy Worldwide

April 29, 2025 | msn.com

SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR

April 28, 2025 | prnewswire.com

SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025

April 22, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATRA, SOPH, ADVM, and INMB Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

$2.25 -0.04 (-1.75%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.25 0.00 (0.00%)

As of 06/20/2025 04:04 PM Eastern

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Atara Biotherapeutics NASDAQ:ATRA

$7.94 -0.08 (-1.00%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$7.97 +0.03 (+0.38%)

As of 06/20/2025 07:12 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

INmune Bio NASDAQ:INMB

$6.38 -0.86 (-11.88%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$6.41 +0.03 (+0.47%)

As of 06/20/2025 07:55 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

SOPHiA GENETICS NASDAQ:SOPH

$3.04 0.00 (0.00%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$3.00 -0.04 (-1.32%)

As of 06/20/2025 07:47 PM Eastern

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time